Suchergebnisse - "Macrocyclic Compounds pharmacology"

Biological Characterization and in Vivo Assessment of the Activity of a New Synthetic Macrocyclic Antifungal Compound.

Autoren: Deodato, D. Maccari, G. De Luca, F. et al.

Schlagwörter: Animals, Antifungal Agents/chemistry, Antifungal Agents/pharmacology, Colony Count, Microbial, Macrocyclic Compounds/chemistry, Macrocyclic Compounds/pharmacology, Mice, Microbial Sensitivity Tests, Microscopy, Fluorescence, Yeasts/drug effects, Yeasts/isolation & purification

Relation: Journal of Medicinal Chemistry; https://iris.unil.ch/handle/iris/192595; serval:BIB_C07763C7CB83; 000375519900018

Verfügbarkeit: https://iris.unil.ch/handle/iris/192595
https://doi.org/10.1021/acs.jmedchem.6b00018

Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real‐world experience study

Autoren: R. Flisiak E. Janczewska M. Łucejko et al.

Quelle: Journal of Viral Hepatitis. 25:1298-1305

Schlagwörter: Male, Cyclopropanes, Liver Cirrhosis, chronic - drug therapy, Hepacivirus, Uracil - analogs & derivatives, 0302 clinical medicine, Liver cirrhosis - drug therapy, 2-Naphthylamine, Ritonavir - therapeutic use, Anilides, Treatment outcome, Liver neoplasms - epidemiology, Middle aged, chronic - virology, Uracil - pharmacology, Viral load - drug effects, Liver Neoplasms, Liver - pathology, Hepatitis C, hepatocellular - epidemiology, 3. Good health, Liver, Drug Therapy, Combination, Female, Drug therapy, Anilides - pharmacology, Uracil - therapeutic use, chronic - pathology, Liver cirrhosis - pathology, Adult, Carcinoma, Hepatocellular, Macrocyclic Compounds, Genotype, Liver cirrhosis - virology, Antiviral agents - therapeutic use, Liver cirrhosis - epidemiology, Lactams, Macrocyclic, Follow-up studies, Liver - physiopathology, Ribavirin - pharmacology, Antiviral Agents, Macrocyclic compounds - therapeutic use, 03 medical and health sciences, Sulfonamides - therapeutic use, chronic - epidemiology, Sulfonamides - pharmacology, Humans, hepatocellular carcinoma, liver cirrhosis, long-term follow-up, sustained virologic response, therapy, viral hepatitis C, Aged, combination, Carbamates - pharmacology, Carcinoma, Macrocyclic compounds - pharmacology, Poland - epidemiology, Hepatitis C, Chronic, Hepacivirus - genetics, Liver - drug effects, Ribavirin - therapeutic use, Ritonavir - pharmacology, Carbamates - therapeutic use, Anilides - therapeutic use, Hepacivirus - drug effects, Carbamates, Antiviral agents - pharmacology, Follow-Up Studies

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/29888828
https://onlinelibrary.wiley.com/doi/10.1111/jvh.12945
https://europepmc.org/article/MED/29888828
https://publicum.umed.lodz.pl/info/article/AML180e3455f40d456dbc7677bd27168393/
https://www.ncbi.nlm.nih.gov/pubmed/29888828
https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.12945
https://doi.org/10.1111/jvh.12945
https://ruj.uj.edu.pl/xmlui/handle/item/143548

Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection

Autoren: Mariusz Łucejko Robert Flisiak Anna Parfieniuk-Kowerda

Quelle: Expert Opinion on Pharmacotherapy. 17:1153-1164

Schlagwörter: Cyclopropanes, 0301 basic medicine, Macrocyclic Compounds, Proline, chronic - drug therapy, Antiviral agents - therapeutic use, Lactams, Macrocyclic, Antiviral Agents, Uracil - analogs & derivatives, Macrocyclic compounds - therapeutic use, 03 medical and health sciences, Sulfonamides - therapeutic use, 2-Naphthylamine, Sulfonamides - pharmacology, Ritonavir - therapeutic use, Humans, Anilides, Uracil, Sulfonamides, 0303 health sciences, Uracil - pharmacology, Ritonavir, Carbamates - pharmacology, Valine, Macrocyclic compounds - pharmacology, Hepatitis C, Chronic, Hepatitis C, 3. Good health, Ritonavir - pharmacology, combination - methods, Carbamates - therapeutic use, Anilides - therapeutic use, Drug Therapy, Combination, Drug therapy, Carbamates, Anilides - pharmacology, Antiviral agents - pharmacology, Uracil - therapeutic use

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/27064432
https://www.tandfonline.com/doi/full/10.1080/14656566.2016.1176143
http://europepmc.org/abstract/MED/27064432

Hepatitis C virus impairs natural killer cell activity via viral serine protease NS3

Weitere Verfasser: College of Medicine Dept. of Microbiology Chang Mo Yang et al.

Schlagwörter: Carbamates/chemistry, Carbamates/pharmacology, Cell Line, Cell Survival/drug effects, Coculture Techniques, Down-Regulation/drug effects, Hepacivirus/enzymology, Hepatitis C/immunology, Hepatitis C/pathology, Hepatitis C/virology, Humans, Interferon-gamma/analysis, Interferon-gamma/metabolism, Interleukin-12/genetics, Interleukin-12/metabolism, Interleukin-12/pharmacology, K562 Cells, Killer Cells, Natural/drug effects, Natural/immunology, Natural/metabolism, Macrocyclic Compounds/chemistry, Macrocyclic Compounds/pharmacology, Microscopy, Confocal, Natural Cytotoxicity Triggering Receptor 1/genetics, Natural Cytotoxicity Triggering Receptor 1/metabolism, Natural Cytotoxicity Triggering Receptor 3/genetics, Natural Cytotoxicity Triggering Receptor 3/metabolism, Quinolines/chemistry

Relation: PLOS ONE; J02540; https://ir.ymlib.yonsei.ac.kr/handle/22282913/154572; T201701200; PLOS ONE, Vol.12(4) : e0175793, 2017; 43622

Verfügbarkeit: https://ir.ymlib.yonsei.ac.kr/handle/22282913/154572
https://doi.org/10.1371/journal.pone.0175793